Evaluation of Safety of a Newly Formulated Pirfenidone in Chronic Kidney Disease: A Non-Randomized Pilot Study in Mexican Patients
The aim of this pilot clinical trial was to evaluate the safety of a new formulation of prolonged-release Pirfenidone (PR-PFD) in chronic kidney disease (CKD), specifically focal and segmental glomerular hyalinization (FSGH). Open-label, pilot, nonrandomized trial. Eighteen patients previously diagn...
Saved in:
| Main Authors: | Simón A. Ojeda-Duran, Iván Lyra-Gonzalez, Alejandra Meza-Rios, Silvia Lucano-Landeros, Ana Sandoval-Rodriguez, Monica Vazquez-Del Mercado, Arturo Santos, Lucia Flores-Contreras, Juan Armendáriz-Borunda |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Troika Publisher
2020-05-01
|
| Series: | Journal of Renal and Hepatic Disorders |
| Subjects: | |
| Online Access: | https://jrenhep.com/index.php/jrenhep/article/view/61 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Can Pirfenidone and Nintedanib Be Alternative Treatment Options for Radiation Pneumonitis?
by: Hikmet COBAN, et al.
Published: (2025-06-01) -
The pulmoprotective effects of pirfenidone against paraquat-induced pulmonary toxicity: a systematic review
by: Sajjad Sadeghi, et al.
Published: (2025-06-01) -
Pirfenidone combined with UC-MSCs reversed bleomycin-induced pulmonary fibrosis
by: Jingran Xu, et al.
Published: (2025-08-01) -
Acneiform drug eruption from pirfenidone
by: Jordyn Puccio, BS, et al.
Published: (2025-07-01) -
Comparison of the Effects of Nintedanib and Pirfenidone on Pulmonary Function Test Parameters and Radiological Findings in Patients with Idiopathic Pulmonary Fibrosis: A Real-Life Study
by: Olcay Aycicek, et al.
Published: (2025-02-01)